Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 17/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.56 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475670 | 1.00 | OPRL1 (0.65) | OPRL1OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL6482856 | 0.88 | OPRL1 (0.58) | OPRL1OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL6486322 | 0.87 | OPRL1 (0.60) | OPRL1OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL6215016 | 0.84 | OPRM1 (0.77) | OPRL1OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL6483501 | 0.81 | OPRM1 (0.60) | OPRL1OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL6482596 | 0.81 | OPRM1 (0.75) | OPRL1OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL6475560 | 0.81 | OPRL1 (0.75) | OPRL1OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL6483134 | 0.81 | OPRL1 (0.72) | OPRL1OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL6476563 | 0.81 | OPRL1 (0.72) | OPRL1OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL6215206 | 0.79 | OPRL1 (0.81) | OPRL1OPRM1OPRK1KCNH2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861425-B2 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | OPRL1, ORMDL3, OGFRL1 | OPRL1 1/4885OPRM1 4/4885OPRK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.